No Data
Guizhou Yibai Pharmaceutical (600594.SH): has actually repurchased 0.95% of the company's shares.
On November 28, 2023, Guizhou Yibai Pharmaceutical (600594.SH) announced that the deadline for the share repurchase has expired. The company has completed the repurchase, having repurchased a total of 7,533,500 shares through centralized bidding. The repurchased shares account for 0.95% of the company's total share capital, with the highest transaction price being 4.10 yuan per share, the lowest price being 2.89 yuan per share, and the average repurchase price being 3.32 yuan per share. The total amount paid is 24,991,703 yuan (excluding transaction commissions and other transaction costs).
Guizhou Yibai Pharmaceutical (600594.SH): Currently, the company's focus on health products is mainly on throat lozenges, instant beverages, and solid beverages.
Gelonghui November 11th | Guizhou Yibai Pharmaceutical (600594.SH) expressed on the investor interaction platform that the company currently has anti-tumor products such as injection L-OHP, Kangsaidi capsules, and Aiyu capsules. Currently, the company's health products are mainly focused on throat lozenges, instant drinks, solid beverages, etc.
Guizhou Yibai Pharmaceutical (600594.SH): The company did not repurchase in October.
On November 1st, Guizhou Yibai Pharmaceutical (600594.SH) announced that in October 2024, the company did not repurchase any shares. As of the end of October 2024, the company has repurchased a total of 5,037,400 shares through centralized competitive trading, accounting for 0.64% of the total share capital. The highest repurchase price was 3.06 yuan per share, the lowest price was 2.89 yuan per share, and the total amount paid was RMB 14,997,308 (excluding transaction fees such as trading commissions).
Report for the third quarter of 2024 of Guizhou Yibai Pharmaceutical Co., Ltd.
Guizhou Yibai Pharmaceutical (600594.SH) released its performance for the first three quarters, with a net loss of 0.169 billion yuan.
Guizhou Yibai Pharmaceutical (600594.SH) released the third quarter report for 2024, with the company's revenue for the first three quarters reaching 17...
Guizhou Yibai Pharmaceutical (600594.SH): The net loss in the first three quarters was 0.169 billion yuan.
On October 25, Guizhou Yibai Pharmaceutical (600594.SH) released the third quarter report for 2024, with the company's revenue for the first three quarters of 1.714 billion yuan, a year-on-year decrease of 19.80%; net income attributable to shareholders of the listed company was -0.169 billion yuan; basic earnings per share was -0.214 yuan.
The Market Doesn't Like What It Sees From Guizhou Yibai Pharmaceutical Co., Ltd.'s (SHSE:600594) Revenues Yet As Shares Tumble 25%
